Catabasis Pharmaceuticals, Inc. CATB, a clinical-stage biopharmaceutical company, today announced that the Company will present results from the open-label extension of the MoveDMD trial following 24 and 36 weeks of edasalonexent treatment in boys with Duchenne Muscular Dystrophy (DMD) at the 22nd International Congress of the World Muscle Society. The late breaking abstract and results will be available in the late breaking poster session starting at 10:30am CEST on Wednesday, October 4, 2017. The International Congress of the World Muscle Society is being held October 3 – 7, 2017, at the Palais du Grand Large in Saint Malo, France.
About Edasalonexent
Edasalonexent (CAT-1004) is an
investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a
protein that is activated in DMD and drives inflammation and fibrosis,
muscle degeneration and suppresses muscle regeneration. We are currently
conducting the MoveDMD trial, a three-part clinical trial investigating
the safety and efficacy of edasalonexent in boys enrolled at ages 4 – 7
affected with DMD (any confirmed mutation). The third part of the trial,
an open-label extension with edasalonexent, is ongoing. The FDA has
granted orphan drug, fast track and rare pediatric disease designations
and the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a summary of
clinical results reported to-date, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted) Linker
drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART LinkerSM platform to build an internal pipeline of
product candidates for rare diseases and plan to pursue partnerships to
develop additional product candidates. For more information on the
Company's drug discovery platform and pipeline of drug candidates,
please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170914005328/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.